Metacrine to Present at 2021 Jefferies Healthcare Conference
May 26 2021 - 8:05AM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with liver
and gastrointestinal diseases, today announced that Preston
Klassen, M.D., MHS, president and chief executive officer, will
present virtually at the 2021 Jefferies Healthcare Conference at
11:00 a.m. ET on Friday, June 4, 2021.
A live webcast of the presentation will be available at
https://investors.metacrine.com/events-and-presentations.
A replay of the webcast will be archived for 30 days following the
conference.
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company
building a pipeline of differentiated therapies to treat liver and
gastrointestinal diseases. Metacrine has developed a proprietary
farnesoid X receptor (FXR) platform utilizing a unique chemical
scaffold, which has demonstrated an improved therapeutic profile in
clinical trials. The Company’s two product candidates, MET409 and
MET642, are currently being investigated in clinical trials as
potential new treatments for NASH. MET409 has completed a 12-week
monotherapy trial in patients with NASH and is being evaluated in a
12-week combination trial with empagliflozin in patients with both
NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1
trial in healthy volunteers and is being evaluated in a 16-week
monotherapy trial in patients with NASH. To learn more, visit
www.metacrine.com.
Investor & Media Contact
Steve Kunszabo
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Apr 2023 to Apr 2024